Could a cholesterol drug boost lung cancer treatment? new trial investigates.
NCT ID NCT06385262
First seen Mar 06, 2026 · Last updated May 03, 2026 · Updated 7 times
Summary
This study tests whether adding a cholesterol-lowering drug (alirocumab) to standard chemotherapy and immunotherapy (cemiplimab) before surgery can improve outcomes for people with early-stage non-small cell lung cancer (stages 1B-3A). About 126 participants will receive either the standard treatment or the standard plus alirocumab. The main goal is to see if the combination leads to no cancer cells remaining in the removed tumor tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.